Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 211-185-4 | CAS number: 632-79-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: inhalation
Administrative data
- Endpoint:
- short-term repeated dose toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1975
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: The study is old, but well reported and included the majority of endpoints typical of a guideline study.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 975
Materials and methods
Test guideline
- Qualifier:
- no guideline available
- Principles of method if other than guideline:
- Whole body inhalation exposures for 5d/wk for 3 weeks.
- GLP compliance:
- no
- Limit test:
- no
Test material
- Reference substance name:
- Tetrabromophthalic anhydride
- EC Number:
- 211-185-4
- EC Name:
- Tetrabromophthalic anhydride
- Cas Number:
- 632-79-1
- Molecular formula:
- C8Br4O3
- IUPAC Name:
- tetrabromo-1,3-dihydro-2-benzofuran-1,3-dione
- Details on test material:
- Micronized FM PHT4 was used as the test article.
Constituent 1
Test animals
- Species:
- rat
- Strain:
- other: Spartan
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- housed individually in temperature and humidity controlled room. Purina Rat Chow and water available ad libitum.
Administration / exposure
- Route of administration:
- inhalation: dust
- Type of inhalation exposure:
- whole body
- Vehicle:
- air
- Details on inhalation exposure:
- Each group placed in sealed 59.1 L gass chambers and exposed to a dynamic atmosphere containing the test article or air only. To prevent piling up during the exposure, rats were separated by sex into 4 units of 2 or 3 rats each. Addition of the test material was controlled by a Wright Dust Feeder. Dired and filtered air was passed through the mechanism and directly into the exposure chamber. Air flow was regulated by a flowmeter.
- Analytical verification of doses or concentrations:
- no
- Duration of treatment / exposure:
- 4 hours, 5 days weekly for 3 weeks.
- Frequency of treatment:
- 5 days weekly for 3 weeks.
Doses / concentrations
- Remarks:
- Doses / Concentrations:
0, 2, 8 mg/L
Basis:
nominal conc.
- No. of animals per sex per dose:
- 5M/5F
Results and discussion
Effect levels
- Dose descriptor:
- NOAEC
- Effect level:
- 2 mg/L air
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: lack of systemic toxicity
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
Statistical analysis not performed.
Mean Male Body Weights (g). SD not available.
Group |
Day of Test |
|||
0 |
7 |
14 |
21 |
|
Control |
248.4 |
280.6 |
308.6 |
326.0 |
2 mg/L |
247.4 |
261.0 |
275.6 |
307.8 |
8 mg/L |
248.0 |
274.4 |
292.8 |
305.6 |
Mean Female Body Weights (g). SD not available.
Group |
Day of Test |
|||
0 |
7 |
14 |
21 |
|
Control |
226.0 |
236.2 |
250.8 |
259.2 |
2 mg/L |
223.8 |
220.4 |
225.0 |
235.4 |
8 mg/L |
220.8 |
222.8 |
232.8 |
229.0 |
Mean Weekly Food Consumption by Male Rats (g). SD not available.
Group |
Week of Test |
|||
0 |
1 |
2 |
3 |
|
Control |
164.4 |
186.4 |
197.2 |
171.6 |
2 mg/L |
164.4 |
159.4 |
173.2 |
167.6 |
8 mg/L |
163.8 |
161.8 |
166.2 |
154.2 |
Mean Weekly Food Consumption by Female Rats (g). SD not available.
Group |
Week of Test |
|||
0 |
1 |
2 |
3 |
|
Control |
138.6 |
135.0 |
148.4 |
141.0 |
2 mg/L |
141.4 |
123.8 |
122.6 |
119.2 |
8 mg/L |
142.8 |
120.6 |
130.6 |
114.6 |
Mean Bromine Content (ppm) of Selected Tissues After 21 Exposures, Male and Female Rats Combined. SD not available.
Group |
Bromine Content (ppm) |
||||
Fat |
Liver |
Lung |
Kidney |
Blood |
|
Control |
1.50 |
3.14 |
11.64 |
8.23 |
7.83 |
8 mg/L |
13.54 |
9.91 |
38.88 |
24.79 |
23.50 |
Applicant's summary and conclusion
- Conclusions:
- NOAEC for systemic toxicity was 2 mg/L in this 3 wk inhalation study in rats.
- Executive summary:
In a 21 d inhalation study, albino rats were exposed to a micronized form of the test article to atmospheric concentrations of 2 and 8 mg/L. Rats were expsosed for 4 h/d, 5 d/wk for 3 wk. A control group was exposed only to air in the test chambers. Observations were made daily and body weights and food consumption measured weekly. Hemtological, biochemical adn urinalysis studies were conducted at 20 d. Bromine analysis by neutron activation of liver, fat, kidney, lung and blood samples were conducted on samples collected at terminal necropsy.
Clinical observations in the treated groups included salivation, lacrimation, nasal discharge, and nasal porphyrin discharge, Respiratory congestion was observed in one animal at the 8 mg/L dose. No deaths occrred in either the control or treated groups. Slightly lower body weights were observed in treated animals than in the controls (statistical analysis was not performed). Food consumption was similar in control and treated animals. No compound-related hematological, biochemical or urinalysis changes were observed. Bromine analysis of selected tissues and blood by neutron activation indicated increased bromine values in the tissues and blood of animals in the 8 mg/L group over that from the control goup. No compound-related gross lesions were observed. A compound-related decrease in liver weight, and increase in lung weight was observed in both exposure levels. An increase in relative adrenal and thyroid weight in females at 8 mg/L may have been compound-related. Microscopically, an increase in inflamatory lung lesions in both experimental groups may have been compound related. No other lesions related to compound administration were seen in other tissues examined from the 8 mg/L group.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.